Palmoplantar pustular psoriasis induced by adalimumab: A case report and literature review

Immunotherapy

Volumn 7, Issue 7, 2015, Pages 717-720

  Ibis, Nurdan ^a   Hocaoglu, Sehriban ^a   Cebicci, Mehtap Aykac ^a   Sutbeyaz, Serap Tomruk ^a   Calis, Havva Talay ^a  

^a KAYSERI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

adalimumab; anti TNF drugs; palmoplantar pustular psoriasis; TNF inhibitors

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; INDOMETACIN; INFLIXIMAB; MELOXICAM; PIMECROLIMUS; PSEUDOMONIC ACID; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; BONE SCINTISCANNING; CASE REPORT; CONSULTATION; DISEASE COURSE; DISEASE DURATION; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LOW BACK PAIN; MEDICAL HISTORY; MORNING STIFFNESS; NECK PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; PAIN SEVERITY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PUSTULE; PUSTULOSIS PALMOPLANTARIS; RASH; SACROILIITIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; PATHOLOGY; PSORIASIS; SPONDYLITIS, ANKYLOSING;

ADALIMUMAB; ADULT; FEMALE; HUMANS; PSORIASIS; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84942105077     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.45     Document Type: Article

References (12)

1. Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G. Tumor necrosis factor-a inhibitor-induced psoriasis or psoriasiform exanthemata. Am. J. Clin. Dermatol. 9(1), 1-14 (2008).
2. Ko JM, Gottlieb AB, Kerbleski JF. Induction and exacerbation of psoriasis with TNF-blockade therapy: A review and analysis of 127 cases. J. Dermatolog. Treat 20(2), 100-108 (2009).
3. Collamer AN, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: clinical features and possible immunopathogenesis. Semin Arthritis Rheum. 40(3), 233-240 (2010).
4. Harrison MJ, Dixon WG, Watson KD et al. Rates of newonset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Ann. Rheum. Dis. 68(2), 209-215 (2009).
5. Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 43(3), 17-23 (2004).
6. Fiorentino DF. The Yin and Yang of TNF-{alpha} inhibition. Arch Dermatol. 143(2), 233-236 (2007).
7. de Gannes GC, Ghoreishi M, Pope J et al. Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch. Dermatol. 143(2), 223-231 (2007).
8. Mössner R, Thaci D, Mohr J et al. Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases. Arch. Dermatol. Res. 300(3), 101-105 (2008)
9. López-Robles A, Queiro R, Alperi M, Alonso S, Riestra JL, Ballina J. Psoriasis and psoriasiform lesions induced by TNFa antagonists: the experience of a tertiary care hospital from northern Spain. Rheumatol. Int. 32(12), 3779-3783 (2012).
10. Cuchacovich R, Espinoza CG, Virk Z, Espinoza LR. Biologic therapy (TNF-[alpha] antagonists)-induced psoriasis: A cytokine imbalance between TNF-[alpha] and IFN-[alpha]? J. Clin. Rheumatol. 14(6), 353-356 (2008).
11. Richetta A, Mattozzi C, Carlomagno V et al. A case of infliximab-induced psoriasis. Dermatol. Online J. 14(11), 9 (2008).
12. Collamer AN, Guerrero KT, Henning JS, Battafarano DF. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: A literature review and potential mechanisms of action. Arthritis Rheum. 59(7), 996-1001 (2008).